Cargando…
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
Progress has been made in COVID-19 vaccine development, with encouraging safety and efficacy data. The purpose of this study was to investigate the immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Patients with AIIRD (n = 101) were i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606114/ https://www.ncbi.nlm.nih.gov/pubmed/36289319 http://dx.doi.org/10.1038/s41598-022-22839-0 |
_version_ | 1784818228649787392 |
---|---|
author | Zheng, Yi-Qing Li, He-Jun Chen, Ling Lin, Shun-Ping |
author_facet | Zheng, Yi-Qing Li, He-Jun Chen, Ling Lin, Shun-Ping |
author_sort | Zheng, Yi-Qing |
collection | PubMed |
description | Progress has been made in COVID-19 vaccine development, with encouraging safety and efficacy data. The purpose of this study was to investigate the immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Patients with AIIRD (n = 101) were included in this study. All patients received 2 doses of inactivated COVID-19 vaccine. Serum anti-S1/RBD protein IgG was detected 2–16 weeks after the second vaccination. Seropositivity was defined as IgG ≥ 1.00 bound antibody unit S/CO. Immunogenicity of inactivated COVID-19 vaccine was assessed by seropositivity rate and the levels of serum IgG antibody against anti-S1/RBD protein, compared with the general population (n = 46). There was no difference by statistical significance in the seropositivity rate between patients with AIIRD (82.2%) and SLE (86.1%) and the control group (93.5%), p > 0.05. The level of anti-S1/RBD protein IgG antibodies in patients with AIIRD (median [IQR], 8.8 [2.2–17.3]) and SLE (median [IQR], 9.6 [2.4–20.4]) was comparable to that in the control group (median [IQR], 7.2 [3.1–14.2]), p > 0.05. Patients treated with glucocorticoids(GCs) (median dose, [IQR]: 2.5 mg/day [IQR 2.5–5.0]) or hydroxychloroquine(HCQ) or GCs + HCQ without other immunomodulatory medications, had an appropriate immunogenic response(88.1%) with high levels of anti-S1/RBD protein IgG(median [IQR], 12.1 [6.5–20.4]). Neither of patients treated with rituximab had positive serum antibodies, which was statistically significant, compared with the control group (p < 0.01). Compared with the control group, methotrexate(MTX) and iguratimod(IGU) was significantly reduced the level of anti-S1/RBD protein IgG antibodies. Inactivated COVID-19 vaccine had appropriate immunogenicity in patients with AIIRD. Immunogenicity of inactivated COVID-19 vaccine was severely impaired by rituximab, and also suppressed by MTX and IGU, while low doses of GC and HCQ had negligible effect. |
format | Online Article Text |
id | pubmed-9606114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96061142022-10-28 Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases Zheng, Yi-Qing Li, He-Jun Chen, Ling Lin, Shun-Ping Sci Rep Article Progress has been made in COVID-19 vaccine development, with encouraging safety and efficacy data. The purpose of this study was to investigate the immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Patients with AIIRD (n = 101) were included in this study. All patients received 2 doses of inactivated COVID-19 vaccine. Serum anti-S1/RBD protein IgG was detected 2–16 weeks after the second vaccination. Seropositivity was defined as IgG ≥ 1.00 bound antibody unit S/CO. Immunogenicity of inactivated COVID-19 vaccine was assessed by seropositivity rate and the levels of serum IgG antibody against anti-S1/RBD protein, compared with the general population (n = 46). There was no difference by statistical significance in the seropositivity rate between patients with AIIRD (82.2%) and SLE (86.1%) and the control group (93.5%), p > 0.05. The level of anti-S1/RBD protein IgG antibodies in patients with AIIRD (median [IQR], 8.8 [2.2–17.3]) and SLE (median [IQR], 9.6 [2.4–20.4]) was comparable to that in the control group (median [IQR], 7.2 [3.1–14.2]), p > 0.05. Patients treated with glucocorticoids(GCs) (median dose, [IQR]: 2.5 mg/day [IQR 2.5–5.0]) or hydroxychloroquine(HCQ) or GCs + HCQ without other immunomodulatory medications, had an appropriate immunogenic response(88.1%) with high levels of anti-S1/RBD protein IgG(median [IQR], 12.1 [6.5–20.4]). Neither of patients treated with rituximab had positive serum antibodies, which was statistically significant, compared with the control group (p < 0.01). Compared with the control group, methotrexate(MTX) and iguratimod(IGU) was significantly reduced the level of anti-S1/RBD protein IgG antibodies. Inactivated COVID-19 vaccine had appropriate immunogenicity in patients with AIIRD. Immunogenicity of inactivated COVID-19 vaccine was severely impaired by rituximab, and also suppressed by MTX and IGU, while low doses of GC and HCQ had negligible effect. Nature Publishing Group UK 2022-10-26 /pmc/articles/PMC9606114/ /pubmed/36289319 http://dx.doi.org/10.1038/s41598-022-22839-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zheng, Yi-Qing Li, He-Jun Chen, Ling Lin, Shun-Ping Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases |
title | Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases |
title_full | Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases |
title_fullStr | Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases |
title_full_unstemmed | Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases |
title_short | Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases |
title_sort | immunogenicity of inactivated covid-19 vaccine in patients with autoimmune inflammatory rheumatic diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606114/ https://www.ncbi.nlm.nih.gov/pubmed/36289319 http://dx.doi.org/10.1038/s41598-022-22839-0 |
work_keys_str_mv | AT zhengyiqing immunogenicityofinactivatedcovid19vaccineinpatientswithautoimmuneinflammatoryrheumaticdiseases AT lihejun immunogenicityofinactivatedcovid19vaccineinpatientswithautoimmuneinflammatoryrheumaticdiseases AT chenling immunogenicityofinactivatedcovid19vaccineinpatientswithautoimmuneinflammatoryrheumaticdiseases AT linshunping immunogenicityofinactivatedcovid19vaccineinpatientswithautoimmuneinflammatoryrheumaticdiseases |